Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.86 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.86 |
| ▸ | SRC | P12931 | 8/20 | 0.80 |
| ▸ | HCK | P08631 | 8/20 | 0.80 |
| ▸ | SYK | P43405 | 5/20 | 0.80 |
| ▸ | GSK3A | P49840 | 5/20 | 0.80 |
| ▸ | GSK3B | P49841 | 2/20 | 0.80 |
| ▸ | BRAF | P15056 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12544626 | 0.93 | MAPK14 (0.87) | MAPK14MAPK12SRCHCKSYK | |
| SCHEMBL2568987 | 0.92 | MAPK14 (1.00) | MAPK14MAPK12SRCHCKSYK | |
| SCHEMBL2492723 | 0.92 | MAPK14 (0.82) | MAPK14MAPK12SRCHCKSYK | |
| SCHEMBL1694192 | 0.92 | MAPK14 (0.87) | MAPK14MAPK12SRCHCKSYK | |
| SCHEMBL2533355 | 0.91 | MAPK14 (0.81) | MAPK14MAPK12SRCHCKSYK | |
| SCHEMBL12540679 | 0.91 | MAPK14 (0.83) | MAPK14MAPK12SRCHCKSYK | |
| SCHEMBL12541119 | 0.91 | MAPK14 (0.86) | MAPK14MAPK12SRCHCKSYK | |
| SCHEMBL13563520 | 0.90 | MAPK12 (0.86) | MAPK14MAPK12SRCHCKSYK | |
| SCHEMBL12541309 | 0.90 | MAPK12 (0.86) | MAPK14MAPK12SRCHCKSYK | |
| SCHEMBL2532428 | 0.90 | MAPK14 (0.84) | MAPK14MAPK12SRCHCKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370429-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-04-20 | — | — | EP | claimed |
| US-20130123260-A1 | Methods | RESPIVERT LIMITED (GB) | 2013-05-16 | — | — | US | claimed |
| US-8299073-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | claimed |
| US-8299074-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | claimed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | claimed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | claimed |
| EP-2582433-B1 | UREIDO-PYRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF RHINOVIRUS INFECTIONS | RESPIVERT LTD (GB) | 2018-04-18 | — | — | EP | disclosed |
| EP-2509595-B1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD (GB) | 2018-04-11 | — | — | EP | disclosed |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| EP-2370429-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-20160045482-A1 | UREIDO-PYRAZOLE DERIVATIVES | RESPIVERT LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| US-20160045512-A1 | Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection | RESPIVERT LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| US-9079893-B2 | Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (RSV) infection | Respivert, Ltd. (GB) | 2015-07-14 | — | — | US | disclosed |
| US-8299074-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8299073-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20120244120-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD. (GB) | 2012-09-27 | — | — | US | disclosed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | disclosed |
| EP-2370429-A1 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010067130-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | MAPK14 25/4885MAPK12 34/4885SRC 634/4885 |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | HCK, CDK9, PHKG1 | MAPK14 257/4885MAPK12 621/4885SRC 384/4885 |
| US-20160045482-A1 | UREIDO-PYRAZOLE DERIVATIVES | CFTR, URB2, PRPF3 | MAPK14 3343/4885MAPK12 3951/4885SRC 4365/4885 |
| US-20120244120-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | HCK, CDK9, TTK | MAPK14 418/4885MAPK12 634/4885SRC 384/4885 |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | MAPK14 10/4885MAPK12 13/4885SRC 229/4885 |
| US-20130123260-A1 | Methods | CFTR, SERPINB1, CMA1 | MAPK14 3580/4885MAPK12 3675/4885SRC 3783/4885 |
| US-20160045512-A1 | Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection | HCK, CDK9, TTK | MAPK14 418/4885MAPK12 634/4885SRC 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.